These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 24723566

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH.
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
    Garton ALA, Kinslow CJ, Rae AI, Mehta A, Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce JN, Canoll P, Cheng SK, Sonabend AM, Wang TJC.
    J Neurosurg; 2021 May 01; 134(5):1357-1367. PubMed ID: 32384274
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases.
    Kanamori M, Kumabe T, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Suzuki H, Watanabe M, Tominaga T.
    Brain Tumor Pathol; 2013 Jul 01; 30(3):151-9. PubMed ID: 23053495
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI.
    Johnson DR, Diehn FE, Giannini C, Jenkins RB, Jenkins SM, Parney IF, Kaufmann TJ.
    AJNR Am J Neuroradiol; 2017 Apr 01; 38(4):678-684. PubMed ID: 28126746
    [Abstract] [Full Text] [Related]

  • 29. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.
    Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M.
    Neuropathol Appl Neurobiol; 2003 Oct 01; 29(5):462-71. PubMed ID: 14507338
    [Abstract] [Full Text] [Related]

  • 30. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
    Brandner S, McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Leal ES, Faulkner CL, Palmer A, Wragg C, Jefferies S, Vale L, Higgins JPT, Kurian KM.
    Neuropathol Appl Neurobiol; 2022 Jun 01; 48(4):e12790. PubMed ID: 34958131
    [Abstract] [Full Text] [Related]

  • 31. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.
    J Natl Cancer Inst; 1998 Oct 07; 90(19):1473-9. PubMed ID: 9776413
    [Abstract] [Full Text] [Related]

  • 32. Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Roux A, Tauziede-Espariat A, Zanello M, Peeters S, Zah-Bi G, Parraga E, Edjlali M, Lechapt E, Shor N, Bellu L, Berzero G, Dormont D, Dezamis E, Chretien F, Oppenheim C, Sanson M, Varlet P, Capelle L, Dhermain F, Pallud J.
    Neuro Oncol; 2020 Jul 07; 22(7):993-1005. PubMed ID: 32025725
    [Abstract] [Full Text] [Related]

  • 33. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S, Caldonazzi N, Simbolo M, Piredda ML, Brunelli M, Poliani PL, Pinna G, Sala F, Ghimenton C, Scarpa A, Barresi V.
    Virchows Arch; 2021 Nov 01; 479(5):987-996. PubMed ID: 34165590
    [Abstract] [Full Text] [Related]

  • 37. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.
    Cancer Sci; 2018 Jul 01; 109(7):2327-2335. PubMed ID: 29752851
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.